http://medicalxpress.com/ en-us Medical Xpress internet news portal provides the latest news on Health and Medicine. A new oral targeted drug, idelalisib (GS-1101), has the potential to stave off the need for additional treatments for relapsed or treatment-resistant chronic lymphocytic leukemia (CLL), according to a study led in part by Dana-Farber Cancer Institute investigators. In a phase 1 clinical trial, the drug produced rapid and long-lasting tumor shrinkage in about two-thirds of patients, stalling disease progression for 17 months, on average. The activity of the drug is noteworthy, given that the patients had an average of five prior therapies. http://medicalxpress.com/news/2013-05-protein-targeting-drug-early-trial-patients.html Cancer Fri, 17 May 2013 08:50:01 EST news287996211 Researchers using patients' own immune cells in an immunotherapy approach called "anti-CD19 chimeric antigen receptor (CAR) T-cell therapy," achieved responses in children whose acute lymphocytic leukemia (ALL) had returned after a bone marrow transplant, according to preliminary results presented at the AACR Annual Meeting 2013, held in Washington, D.C., April 6-10. http://medicalxpress.com/news/2013-04-immunotherapy-antileukemia-pediatric-patients.html Cancer Sun, 07 Apr 2013 17:14:23 EST news284573651 The powerful master regulatory transcription factor called Bcl6 is key to the survival of a majority of aggressive lymphomas, which arise from the B-cells of the immune system. The protein has long been considered too complex to target with a drug since it is also crucial to the healthy functioning of many immune cells in the body, not just B cells gone bad. http://medicalxpress.com/news/2013-03-shutdown-cancer-powerful-master-protein.html Immunology Sun, 03 Mar 2013 13:00:24 EST news281519760 Cancer is thought to arise from DNA damage at fragile sites in the genome. A study published by Cell Press on January 24th in the journal Cell reveals a new class of fragile sites that contributes to DNA alterations in a type of blood cancer called B cell lymphoma The findings could lead to the development of more effective treatments for B cell lymphoma and potentially other cancers. http://medicalxpress.com/news/2013-01-discovery-class-damage-prone-dna-regions.html Cancer Thu, 24 Jan 2013 12:00:11 EST news278249780 How do you annihilate lymphoma without using any drugs? Starve it to death by depriving it of what appears to be a favorite food: HDL cholesterol. http://medicalxpress.com/news/2013-01-golden-nanoparticles-lymphoma-chemotherapy.html Cancer Mon, 21 Jan 2013 15:00:10 EST news277985716 A potent chemotherapy agent wrapped within a monoclonal antibody selectively destroys the malignant cells responsible for acute lymphocytic leukemia (ALL) in either weekly or monthly dosing, researchers report at the 54th ASH Annual Meeting and Exposition. http://medicalxpress.com/news/2012-12-weekly-dose-drug-side-effects.html Cancer Tue, 11 Dec 2012 13:05:55 EST news274453533 Many observational epidemiologic studies have found an inverse association between alcohol consumption and hematological cancers (such as lymphoma and leukemia). This study, based on the Million Women's Study in the UK, is large enough to permit an evaluation of associations with various types of such cancers. Further, it takes into account newer coding systems for morphology so that diseases associated with the lymphatic system can be separated from those of the myeloid system. http://medicalxpress.com/news/2012-11-effects-alcohol-lymphoma-leukemia-hematological.html Cancer Tue, 13 Nov 2012 13:12:38 EST news272034674 Researchers studying the molecular signals that drive a specific type of lymphoma have discovered a key biological pathway leading to this type of cancer. Cancerous cells have been described as being "addicted" to certain oncogenes (cancer-causing genes), and the new research may lay the groundwork for breaking that addiction and effectively treating aggressive types of B cell lymphoma. http://medicalxpress.com/news/2012-05-protein-cell-lymphoma.html Cancer Mon, 07 May 2012 16:02:43 EST news255625320 B cell lymphomas are a group of cancers of that originate in lymphoid tissue from B cells, the specialized immune cell type that produces antibodies. The development of B cell lymphoma is associated with several known genetic changes, including increased expression of MYC, a transcription factor that promotes cell growth and division. http://medicalxpress.com/news/2012-04-lymphoma-therapy.html Cancer Mon, 30 Apr 2012 13:35:34 EST news255011679 An international team of scientists in Japan, Switzerland, and the United States has confirmed that combining chemotherapy and immunotherapy in cancer treatment enhances the immune system's ability to find and eliminate cancer cells, even when the cancer-associated proteins targeted by the immune system are hidden behind the cancer cell membrane. In a study published in Cancer Research by Noguchi et al., the scientists show that antibodies, which have been successful in treating certain types of cancers, can effectively reach elusive intracellular targets, delaying tumor growth and prolonging survival when combined with chemotherapy. http://medicalxpress.com/news/2012-02-antibodies-intracellular-cancer-antigens-combined.html Cancer Mon, 13 Feb 2012 14:58:35 EST news248367503 Younger patients with diffuse large B-cell lymphoma given a more intensive regimen of chemotherapy combined with rituximab survive significantly longer, and are approximately twice as likely to remain in remission 3 years later, compared with patients given standard chemotherapy treatment plus rituximab, according to an article published Online First in the Lancet. http://medicalxpress.com/news/2011-11-intensive-chemotherapy-recurrence-survival-younger.html Cancer Thu, 24 Nov 2011 18:30:03 EST news241362774 The Max Cure Foundation and the Samuel Waxman Cancer Research Foundation have partnered to establish a fund in pediatric cancer research. With that goal in mind, the two Foundations are proud to announce the award of $100,000 to Erwin G. Van Meir, Ph.D., of Emory University School of Medicine in Atlanta. Van Meir's research aims to reprogram Ewing sarcoma using a small molecule that will target the Ewing sarcoma family of tumors (ESFT) oncoprotein. http://medicalxpress.com/news/2011-07-ewing-sarcoma-family-tumors.html Cancer Fri, 01 Jul 2011 05:24:04 EST news228716635 Researchers from the University of Sheffield have discovered valuable insight into how people develop B-cell lymphoma, one of the most common cancers in the UK. http://medicalxpress.com/news/2011-06-breakthrough-common-cancer.html Cancer Thu, 09 Jun 2011 05:03:00 EST news226814491